JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

Начало・Списък с акции・Essa Pharma Inc

Essa Pharma Inc

Затворен

1.87

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.84

Максимум

1.88

Ключови измерители
By Trading Economics
Приходи	2.2M -6.4M
EPS	-0.14
Служители	35
EBITDA	-2.2M -8.5M

Пазарни показатели
By TradingEconomics
Пазарна капитализация	7M 83M
Предишно отваряне	1.87
Предишно затваряне	1.87

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

1.7 / 1.72 Подкрепа & съпротива

Essa Pharma Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.07.2025 г., 23:56 ч. UTC

Горещи акции

Stocks to Watch: Amazon, Bio-Rad, Coinbase, Mercer

31.07.2025 г., 23:48 ч. UTC

Пазарно говорене

Scentre Can Beat Annual Earnings Guidance -- Market Talk

31.07.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over Earnings, Domestic Politics -- Market Talk

31.07.2025 г., 23:37 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

31.07.2025 г., 23:37 ч. UTC

Пазарно говорене

Gold Steady as Traders Eye Tariff-Deal Developments -- Market Talk

31.07.2025 г., 23:12 ч. UTC

Печалби

OCBC: Evolving Trade, Monetary Policies, Persistent Geopolitical Tensions Expected to Weigh on Growth Prospects >O39.SG

31.07.2025 г., 23:10 ч. UTC

Печалби

Oversea-Chinese Banking: Declining Interest-Rate Environment Weighed in Net Interest Income >O39.SG

31.07.2025 г., 23:09 ч. UTC

Печалби

Oversea-Chinese Banking 2Q Net Interest Income S$2.28B Vs. S$2.43B >O39.SG

31.07.2025 г., 23:08 ч. UTC

Печалби

Oversea-Chinese Banking 2Q Total Income S$3.55B Vs. S$3.63B >O39.SG

31.07.2025 г., 23:08 ч. UTC

Печалби

Oversea-Chinese Banking 2Q Net S$1.82B Vs. Net S$1.94B >O39.SG

31.07.2025 г., 23:01 ч. UTC

Печалби

Amazon Posts Higher Sales, Profit -- 3rd Update

31.07.2025 г., 22:08 ч. UTC

Пазарно говорене

Печалби

Amazon CEO Impressed by Deals Signed for Project Kuiper -- Market Talk

31.07.2025 г., 22:02 ч. UTC

Пазарно говорене

Печалби

Apple's FY Outlook Shows Sales Growth Won't Last -- Market Talk

31.07.2025 г., 21:57 ч. UTC

Пазарно говорене

Печалби

Amazon CEO Sees Strong Early Demand for Alexa+ -- Market Talk

31.07.2025 г., 21:50 ч. UTC

Печалби

Amazon Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

31.07.2025 г., 21:43 ч. UTC

Печалби

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- 2nd Update

31.07.2025 г., 21:29 ч. UTC

Печалби

Amazon to Invest More in Chips, Data Centers Amid Generative AI Opportunity, CFO Says

31.07.2025 г., 21:26 ч. UTC

Печалби

Apple Expects Revenue to Grow in Mid- to High-Single Digits in Current Quarter, CFO Says

31.07.2025 г., 21:26 ч. UTC

Печалби

MicroStrategy Beats Earnings Estimates. The Stock Rises. -- Barrons.com

31.07.2025 г., 21:22 ч. UTC

Печалби

Amazon Has Impressive Amount of Agreements for Project Kuiper, CEO Says

31.07.2025 г., 21:19 ч. UTC

Печалби

Apple Estimates Tariff Impact to Add $1.1B to Costs in Current Quarter, CEO Says

31.07.2025 г., 21:19 ч. UTC

Печалби

Apple Incurred $800M in Tariff-Related Costs in 2Q, CEO Says

31.07.2025 г., 21:14 ч. UTC

Печалби

Amazon's AWS is Seeing More Demand Than Supply, CEO Says

31.07.2025 г., 21:12 ч. UTC

Печалби

Amazon Saw Record Prime Sign-Ups in 3 Weeks Before Prime Day, CEO Says

31.07.2025 г., 21:10 ч. UTC

Печалби

Amazon Just Getting Started on Automation, Robotics to Boost Efficiency, CEO Says

31.07.2025 г., 21:09 ч. UTC

Печалби

Amazon Delivered to Prime Members at Record Pace in 2Q, CEO Says

31.07.2025 г., 21:09 ч. UTC

Печалби

Amazon CEO Sees Diversity of Sellers as Advantage for Inflation-Weary Consumers

31.07.2025 г., 21:08 ч. UTC

Печалби

Apple iPhone Revenue Performance Driven by Popularity of iPhone 16 Family, CEO Says

31.07.2025 г., 21:08 ч. UTC

Печалби

Amazon CEO Sees Strong Customer Adoption of Perishables Same-Day Delivery Pilot

31.07.2025 г., 21:05 ч. UTC

Печалби

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- Update

Сравнение с други в отрасъла

Ценова промяна

Essa Pharma Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Essa Pharma Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.7 / 1.72Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Essa Pharma Inc

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.